Thrombotic Thrombocytopenic Purpura (TTP)

Overview

Thrombotic thrombocytopenic purpura (TTP) is a rare, life‑threatening blood disorder characterized by the formation of small clots (thrombi) in the tiniest blood vessels throughout the body. These clots use up platelets, causing a low platelet count (thrombocytopenia), and they also shear red blood cells, leading to hemolytic anemia. The classic clinical picture—often called the “pentad”—includes:

• Fever
• Neurologic changes (confusion, headaches, seizures)
• Renal dysfunction
• Micro‑angiopathic hemolytic anemia
• Thrombocytopenia

Although the full pentad appears in only ~10–20 % of patients, any combination of these signs should raise suspicion.

Who is affected? TTP can occur at any age but peaks in two groups: young women of childbearing age (often related to pregnancy or autoimmune disease) and adults over 50 with underlying medical conditions. The overall incidence in the United States is about 4–6 cases per million people per year, and mortality historically exceeded 90 % before modern therapy. With prompt plasma exchange and immunosuppression, survival now exceeds 80–90 % (Mayo Clinic, 2023; WHO, 2022).

Symptoms

Symptoms develop rapidly—often over hours to a few days—and may be subtle at first. The following list includes the most common presentations and less‑frequent manifestations.

Hematologic

• Thrombocytopenia – Bruising, petechiae (tiny red spots), or spontaneous bleeding from gums, nose, or gastrointestinal tract.
• Micro‑angiopathic hemolytic anemia (MAHA) – Dark urine, jaundice, fatigue, and a rapid heart rate due to anemia.

Neurologic

• Headache (often severe)
• Confusion, disorientation, or “brain fog”
• Visual disturbances (blurry vision, scotomas)
• Seizures or focal neurologic deficits (weakness, speech difficulty)
• Coma (rare, but possible in severe cases)

Renal

• Mild to moderate kidney dysfunction – elevated creatinine, reduced urine output.
• Hematuria (blood in urine) or proteinuria.

Cardiovascular

• Chest pain or myocardial ischemia due to microvascular clots (reported in ~10 % of cases).

Other Systemic

• Fever – often low‑grade but can be high.
• Pancreatitis‑like abdominal pain (occasionally reported).
• Pregnancy‑related symptoms when TTP occurs in the third trimester (e.g., sudden hypertension, pre‑eclampsia‑like picture).

Causes and Risk Factors

TTP is fundamentally a disorder of the von Willebrand factor (vWF)‑cleaving enzyme ADAMTS13. When ADAMTS13 activity falls <10 % of normal, ultra‑large vWF multimers persist, prompting platelet aggregation and microthrombi formation.

Types of TTP

• Acquired (immune‑mediated) TTP – Autoantibodies inhibit ADAMTS13 (≈ 80 % of cases). Triggers include infections, certain drugs, pregnancy, and autoimmune diseases such as systemic lupus erythematosus.
• Congenital (hereditary) TTP – Mutations in the ADAMTS13 gene (aka Upshaw‑Schulman syndrome). Usually presents in infancy or early childhood, but milder forms may appear later.

Risk Factors

• Female sex (approximately 2–3 : 1 female‑to‑male ratio)
• Pregnancy, especially the third trimester or postpartum period
• Autoimmune disorders (SLE, antiphospholipid syndrome)
• Recent viral infections (e.g., HIV, influenza, COVID‑19)
• Medications: quinine, ticlopidine, clopidogrel, cyclosporine, cyclosporine‑derived agents, some chemotherapeutics
• Underlying malignancy (particularly solid tumors and lymphomas)

Diagnosis

Because TTP progresses quickly, clinicians must act on clinical suspicion while awaiting confirmatory tests.

Initial Laboratory Evaluation

• Complete blood count (CBC) – Low platelet count (<30 × 10⁹/L) and anemia with reticulocytosis.
• Peripheral blood smear – Presence of schistocytes (fragmented RBCs) indicates MAHA.
• Lactate dehydrogenase (LDH) – Markedly elevated due to hemolysis.
• Haptoglobin – Usually undetectable (consumed by free hemoglobin).
• Serum bilirubin – Indirect hyperbilirubinemia.
• Coagulation profile (PT, aPTT, fibrinogen) – Typically normal, helping differentiate from disseminated intravascular coagulation (DIC).
• Renal function tests (creatinine, BUN) – May be normal or mildly elevated.

Specific ADAMTS13 Testing

• Activity assay – Quantifies ADAMTS13 activity; <10 % activity confirms TTP.
• Inhibitor assay – Detects anti‑ADAMTS13 antibodies (useful for acquired TTP).
• Results may take several days; treatment should not be delayed while waiting.

Additional Studies

• Chest X‑ray or CT brain if neurologic symptoms are severe.
• Urinalysis for hematuria/proteinuria.
• Pregnancy testing in women of childbearing age.

Scoring Systems

The PLASMIC score (Platelets, combined hemolysis variables, no active cancer, no solid organ or stem‑cell transplant, MCV < 90 fL, INR < 1.5, Creatinine < 2 mg/dL) helps estimate pre‑test probability of severe ADAMTS13 deficiency and guides early plasma‑exchange initiation (Bahar et al., 2022).

Treatment Options

Immediate therapy is critical; mortality rises >30 % when treatment is delayed >48 hours.

First‑Line Therapy

• Therapeutic plasma exchange (TPE) – Removes auto‑antibodies and supplies functional ADAMTS13. Standard: 1–1.5 L plasma exchanged daily until platelet count >150 × 10⁹/L for two consecutive days and LDH normalizes.
• Glucocorticoids – Prednisone 1 mg/kg/day or methylprednisolone 1 mg/kg IV daily. Reduces antibody production.

Adjunct Immunosuppression

• Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks; shown to shorten time to remission and lower relapse rates (Scully et al., 2021).
• Cyclophosphamide, azathioprine, or mycophenolate mofetil – Considered for refractory disease.
• Caplacizumab – Nanobody that blocks vWF‑platelet interaction; FDA‑approved (2020) for acquired TTP. Improves time to platelet normalization and reduces mortality (Phase III HERCULES trial, 2020).

Supportive Care

• Transfusion of red blood cells for symptomatic anemia (avoid platelet transfusion unless life‑threatening bleeding).
• Renal monitoring, electrolytes, and avoidance of nephrotoxic drugs.
• Antiepileptic drugs if seizures occur.
• Vigilant infection control – patients are immunosuppressed.

Management of Congenital TTP

• Regular prophylactic plasma infusions (10–15 mL/kg every 2–3 weeks) to maintain ADAMTS13 activity.
• Recombinant ADAMTS13 (rADAMTS13, under clinical investigation) may become the future of therapy.

Living with Thrombotic Thrombocytopenic Purpura (TTP)

Even after remission, many patients require long‑term monitoring and lifestyle adjustments.

Follow‑up Schedule

• First month: weekly CBC, LDH, and renal panel.
• Months 2‑6: bi‑weekly to monthly labs.
• After 6 months: quarterly labs, and annual ADAMTS13 activity check.

Recognizing Relapse

Early signs include a drop in platelets <50 × 10⁹/L, rising LDH, or new neurologic symptoms. Prompt contact with a hematologist is essential; many relapses are managed with repeat plasma exchange and rituximab.

Daily Management Tips

• Maintain a balanced diet rich in iron and folate to support red‑cell production.
• Stay hydrated; dehydration can exacerbate hemolysis.
• Avoid over‑the‑counter NSAIDs or aspirin unless directed, as they increase bleeding risk.
• Carry a medical alert card or bracelet stating “History of TTP – requires urgent plasma exchange if bleeding or neurologic changes occur.”
• Vaccinations: keep up‑to‑date, especially influenza and COVID‑19, but discuss timing with your hematologist if you are on immunosuppressants.
• Pregnancy planning: pre‑conception counseling with a hematologist and maternal‑fetal medicine specialist is crucial.

Prevention

Because most TTP cases are immune‑mediated, primary prevention focuses on minimizing known triggers.

• Inform healthcare providers of your TTP history before any surgery, medications, or transfusions.
• Avoid quinine‑containing beverages (e.g., tonic water) if you have a known sensitivity.
• Discuss alternative antiplatelet or anticoagulant drugs if you need them; some agents (e.g., clopidogrel) have been implicated.
• Prompt treatment of infections—particularly viral illnesses—may reduce the chance of an immune flare.
• For congenital TTP, adherence to regular prophylactic plasma infusions is the most effective preventive measure.

Complications

If not promptly treated, TTP can cause irreversible organ damage.

• Neurologic injury – Stroke, seizures, cognitive deficits.
• Renal failure – Acute tubular necrosis, may require dialysis.
• Cardiac ischemia – Micro‑infarctions leading to heart failure.
• Persistent hemolysis – Gallstones, chronic fatigue.
• Relapse – Up to 30–40 % of acquired TTP patients experience at least one recurrence.
• Treatment‑related complications – Central line infections, allergic reactions to plasma, bleeding from over‑correction of platelets.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Thrombotic Thrombocytopenic Purpura (TTP).” 2023; CDC. “Thrombotic Thrombocytopenic Purpura.” 2022; National Institutes of Health (NIH) Hematology guidelines, 2022; WHO “Rare Hematologic Disorders” 2022; Scully M. et al., Blood 2021; HERCULES trial, NEJM 2020; Bahar K. et al., “PLASMIC Score Validation,” J Thromb Haemost 2022.